Overall, OXT008 showed significant anti-cancer effects both in vitro and in vivo in thyroid cancer lines expressing Gal-1, supporting further investigation of the molecular mechanisms of the drug and future clinical trials in patients with anaplastic thyroid cancer. This evidence concerns the gene LGALS1 and thyroid gland undifferentiated (anaplastic) carcinoma.